Home Business Health AstraZeneca To Invest $1.5b To Manufacture Cancer Killer In Singapore
Health

AstraZeneca To Invest $1.5b To Manufacture Cancer Killer In Singapore

Share
Share

AstraZeneca says it  will invest 1.5 billion U.S. dollars in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs).

The biopharmaceutical giant announced on Monday.

AstraZeneca aimed to start designing and construction of the manufacturing facility by the end of this year, with targeted operational readiness from 2029.

According to the company ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody

Share

Businesstoday Magazine

Businesstoday Conference/Awards

Related Articles

Over 135,000 People Living With HIV In Lagos- Says Commissioner

The Lagos State Commissioner for Health, Professor Akin Abayomi, has revealed that...

NAFDAC Strengthens Regulatory Framework For Bioequivalence Studies In Nigeria

The National Agency for Food and Drug Administration and Control (NAFDAC), has...

Sir Emeka Offor Commits US$5 million To Rotary’s Maternal and Child Health Program In Nigeria  

Nigerian Rotary member and philanthropist Sir Emeka Offor has committed US$5 million...

IWD 2025: Leadway Health HMO Champions Women’s Health

In recognition of International Women’s Month this March, Leadway Health HMO has...